RedHill Biopharma Ltd. (RDHL) stock forecast & analysis
0.9000
NasdaqCM · USD
Up: +0.2390, +36.2%
1 analysis
- Open
- 1.36
- Previous close
- 0.6610
- Day range
- 0.9000 – 1.60
- 52-week range
- 0.5700 – 2.79
- Volume (shares)
- 102.87M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 6.08M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 4.90
- Market cap
- 5.47M
Market Scanner’s AI analysis of RedHill Biopharma Ltd. (RDHL), updated September 2026: RedHill Biopharma's Talicia divestiture and Rebyota/Clenpiq acquisition drove significant stock movement amid mixed financial and technical indicators.
Summary
RedHill Biopharma's Talicia divestiture and Rebyota/Clenpiq acquisition drove significant stock movement amid mixed financial and technical indicators.
Recent analyses for RedHill Biopharma (RDHL) covered a significant divestiture of Talicia® and the acquisition of commercialization rights for Rebyota® and Clenpiq®, which led to a substantial stock price increase. The company operates in the Specialty & Generic Drug Manufacturers industry with a negative profit margin but showed improvement in net income over recent years. Technical indicators suggest overbought conditions with the stock trading above the upper Bollinger Band, while also showing upward momentum on the MACD.
RDHL news & sentiment
News reports highlighted significant stock price movement following RedHill Biopharma's Talicia divestiture and acquisition of Rebyota® and Clenpiq®. Social media discussion was not covered in the provided notes.
RDHL technical picture
The stock price traded above the upper Bollinger Band, suggesting a potential pullback, while momentum readings from the MACD indicated upward movement. The current price was positioned above the 10-day EMA but below the 50-day and 200-day SMAs, with overbought conditions noted by the RSI and MFI.
Fundamentals
The company reported trailing twelve months revenue and gross profit, alongside negative profit and operating margins. Net income showed significant year-over-year improvement, moving from substantial losses to a positive figure in 2023 before a smaller loss in the latest reported quarter. Total debt was reported against total cash on the balance sheet.
Factors discussed — upside
- Divestiture of Talicia® for $18 million upfront plus milestones.
- Acquisition of commercialization rights for Ferring's Rebyota® and Clenpiq®.
- Net income showed improvement from prior years, moving from significant losses to a positive figure in 2023 before a smaller loss in the latest reported quarter.
- Positive outlook for the Nontuberculous Mycobacterial Infections market.
- MACD showing a positive value indicating upward momentum.
Factors discussed — risks
- Negative Profit Margin of -1.5% and negative Operating Margin TTM of -27.65%.
- Stock price trading above the upper Bollinger Band, suggesting potential for a pullback.
- RSI at 76.33 and MFI at 99.93 indicating overbought conditions.
- Current stock price below the 50-day and 200-day SMAs.
- Divestiture and Acquisition Activity
- Financial Performance Trends
- Technical Indicators
- Market and Disease Context
Summary updated .
RDHL technical indicators
Common technical indicators for RDHL, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.70 | Price above |
| 10-day exponential moving average | 0.67 | Price above |
| Relative strength index (14-day) | 76.33 | Overbought |
| MACD line (12/26/9) | 0.0054 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.49 – 0.76 | Price above the upper band |
Analyses
Recent RDHL.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for RedHill Biopharma Ltd.?
- The bull case for RedHill Biopharma centers on strategic corporate actions, including the divestiture of Talicia® for significant upfront and milestone payments, and the acquisition of commercialization rights for Rebyota® and Clenpiq®. These moves are supported by improving net income trends and a positive market outlook for Nontuberculous Mycobacterial Infections, alongside technical indicators like positive MACD momentum.
- What are the risks for RedHill Biopharma Ltd.?
- Risks for RedHill Biopharma include its current negative profit and operating margins, alongside technical indicators such as the Relative Strength Index and Money Flow Index suggesting overbought conditions, with the stock price trading above the upper Bollinger Band and below longer-term moving averages.
- Is RedHill Biopharma Ltd. bullish or bearish?
- Recent AI analyses of RedHill Biopharma Ltd. examined factors on both sides. Discussed upside: The bull case for RedHill Biopharma centers on strategic corporate actions, including the divestiture of Talicia® for significant upfront and milestone payments, and the acquisition of commercialization rights for Rebyota® and Clenpiq®. These moves are supported by improving net income trends and a positive market outlook for Nontuberculous Mycobacterial Infections, alongside technical indicators like positive MACD momentum. Discussed risks: Risks for RedHill Biopharma include its current negative profit and operating margins, alongside technical indicators such as the Relative Strength Index and Money Flow Index suggesting overbought conditions, with the stock price trading above the upper Bollinger Band and below longer-term moving averages. These are descriptive observations, not a recommendation.
- What is the latest sentiment on RedHill Biopharma Ltd.?
- News reports highlighted significant stock price movement following RedHill Biopharma's Talicia divestiture and acquisition of Rebyota® and Clenpiq®. Social media discussion was not covered in the provided notes.
- Bundles used
- gemini-low-v2
Run a fresh RDHL.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every RDHL.US report already in the library